Paul Kolm, PhD is the associate director of the Center for Biostatistics, Informatics, and Data Science at MedStar Health Research Institute. He received his PhD from the University of Nebraska-Lincoln Statistics and Measurements. He has 40+ years of experience consulting with principal investigators in designing and analyzing clinical trials, retrospective and observational studies, and large patient registries.
Dr. Kolm has experience in applying general and generalized linear and nonlinear models, multilevel models, classification and tree regression, time-to-event analysis, multivariate analysis, cost-effectiveness analysis, multiple imputation methods for missing data, and analysis of sparse outcomes. He also has training and experience in psychometrics, test and survey design, and analysis and measurement theory.
Dr. Kolm has been a co-investigator and lead biostatistician on many NIH- and industry-funded research projects and wrote the statistical analysis plans for many landmark studies, including the CMS funded “Bridging the Divides,” the NHLBI-funded “HCMR – Novel Predictors of Prognosis in Hypertrophic Cardiomyopathy,” and the DoD-funded BADER Consortium. He is the lead biostatistician for the economic analysis of the recently published “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia” (NEJM). He previously authored or co-authored cost and cost-effectiveness studies for cardiovascular randomized trials, including CURE, CREDO, and COURAGE.